All In Biotech

Drug Trial Radar · NCT05462587

A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II

A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II (LAD II)

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

4

Planned (sponsor's estimate)

Start

Jul 28, 2022

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
AUG TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).

Conditions

  • Leukocyte Adhesion Deficiency

Interventions

  • AVTX-803 (L-Fucose)Drug

    L-fucose crystalline powder

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of AVTX-803 on the percent of leukocytes expressing Sialyl-Lewis X antigenTime frame: Change from Baseline at Day 56, Change from Baseline at Day 112

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.